Biointron launches RushDATA platform for AI antibody discovery

Biointron has launched RushDATA™, an integrated wet-lab validation platform for AI- and machine learning-driven antibody discovery. The company says it can deliver experimental data in 2 days for cell-free expression or 3 days for CHO cell expression.
- RushDATA™ combines antibody expression, binding analysis and developability profiling.
- Biointron cites 2-day cell-free and 3-day CHO cell sequence-to-data turnaround.
- The platform can support 10,000+ antibodies expressed per day.
- Service packages range from rapid screening to developability profiling.
- The corrected release updates the platform name to RushDATA™.
A faster path from antibody sequence to data
Biointron Biological USA Inc., an antibody discovery, expression and optimization contract research organization, said RushDATA™ is designed to address a bottleneck in computational antibody design. AI and machine learning models can generate hundreds to thousands of candidate antibody sequences in one design cycle, according to the company, while experimental validation is often divided among separate expression, binding characterization and developability testing workflows.
Biointron said this traditional process can take 3-4 weeks or longer. RushDATA™ brings antibody expression, binding analysis and optional early developability profiling into one standardized workflow. The resulting structured datasets are intended for AI/ML model training, validation and optimization.
High-throughput expression and characterization
The platform uses both cell-free expression and CHO cell expression. Biointron describes CHO cells as the industry gold standard for therapeutic antibody expression and says the approach supports human-like post-translational modifications, proper protein folding and clinically relevant developability characteristics.
RushDATA™ has capacity for 10,000+ antibodies expressed per day, while its workflows can process 3,000+ molecules per batch in parallel. The platform provides standardized, structured data for scientists and machine-readable AI pipelines. Binding characterization can use BLI and/or SPR and is integrated with expression and purity data.
Selected packages include early developability assessments. These can cover differential scanning fluorimetry for thermal stability, AC-SINS for self-interaction behavior, and polyspecificity reagent binding, or PSR-BVP, for polyreactivity.
Service options for discovery programs
Biointron offers RushDATA™ through three service options. The Basic package provides rapid screening with expression, titer and affinity testing. The Standard package focuses on binding characterization and includes expression, concentration, cGE and affinity testing. The Premium package adds early developability assessments to binding characterization.
The company said it has more than 14 years of experience and has provided services to 3,000+ biopharma companies worldwide. Biointron was founded in 2012 and says it is trusted by 3,000+ organizations in 20+ countries and regions, including top 20 pharma companies.
For users developing AI-designed antibodies, the platform's stated value is the combination of rapid sequence-to-data turnaround, high-volume expression and integrated characterization. Biointron also says RushDATA™ results are ready to feed customer models via API. The company issued a correction stating that the platform name has been corrected from RushData to RushDATA™ and that its listed features were expanded for clarity and accuracy.
PR Newswire: /C O R R E C T I O N - Biointron/


